Alpha 2.0
Login Register
» Authors » Hewen Yin

Hewen Yin

Explore the profile of Hewen Yin including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 21
Followers 0
Related Specialties
Hematology
Biochemistry
Chemistry
Top 10 Co-Authors
Liqing Wu
Shanshan Suo
Jie Jin
Yi Zhang
Hu Zhou
Xin Du
Huanling Zhu
Sujun Gao
Qingchi Liu
Xiaobing Wang
Published In
Am J Hematol
Front Pharmacol
Talanta
Bioelectrochemistry
Blood Cancer J
Affiliations
Soon will be listed here.
Recent Articles
1.
Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study
Zhang Y, Zhou H, Suo S, Zhuang J, Yang L, He A, et al.
Blood Cancer J . 2024 Dec; 14(1):216. PMID: 39695117
To compare the efficacy and safety of gecacitinib (also known as jaktinib) with hydroxyurea (HU) in treating myelofibrosis (MF) patients. In this multicenter, randomized phase 3 trial (ZGJAK016), intermediate- or...
2.
Construction of poly (ionic liquid)-derived gold/silver alloy@nitrogen-doped carbon shell and its application for ratiometric electrochemical detection of nitric oxide
Zhou Y, Yin H, Li J, Shao K, Dong H, Ling C, et al.
Talanta . 2024 Mar; 272:125839. PMID: 38428134
A nitrogen-doped carbon shell loaded with a gold and silver alloy (Au/Ag@NCS) was constructed for highly sensitive electrochemical detection of NO. The Au/Ag@NCS material was prepared by use of SiO...
3.
Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis
Zhang Y, Zhou H, Jiang Z, Wu D, Zhuang J, Li W, et al.
Am J Hematol . 2024 Feb; 99(4):774-779. PMID: 38343062
Jaktinib, a novel JAK and ACVR1 inhibitor, has exhibited promising results in treating patients with myelofibrosis (MF). ZGJAK002 is a Phase 2 trial aimed to assess the efficacy and safety...
4.
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study
Zhang Y, Zhou H, Duan M, Gao S, He G, Jing H, et al.
Am J Hematol . 2023 Jul; 98(10):1588-1597. PMID: 37470365
Although ruxolitinib improves splenomegaly and constitutional symptoms in patients with myelofibrosis (MF), a substantial proportion of patients discontinue ruxolitinib because of intolerance. This phase 2 trial investigated the safety and...
5.
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single-arm, open-label, phase 2, multicenter study
Zhang Y, Zhang Q, Liu Q, Dang H, Gao S, Wang W, et al.
Am J Hematol . 2023 Jul; 98(10):1579-1587. PMID: 37466271
Ruxolitinib has demonstrated efficacy in patients with myelofibrosis (MF). However, substantial number of patients may not respond after 3-6 months of treatment or develop resistance over time. In this phase...
6.
Controllable preparation of silver-doped hollow carbon spheres and its application as electrochemical probes for determination of glycated hemoglobin
Yang Y, Dong H, Yin H, Gu J, Zhang Y, Xu M, et al.
Bioelectrochemistry . 2023 Apr; 152:108450. PMID: 37116231
Silver-doped hollow carbon spheres (Ag@HCS) were firstly introduced as electrochemical probes for glycated hemoglobin (HbA) sensing at a molecularly imprinted polymer (MIP)-based carbon cloth (CC) electrode. Herein, Ag@HCS was prepared...
7.
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Ascending Dose and Food Effect Study to Evaluate the Tolerance, Pharmacokinetics of Jaktinib, a New Selective Janus Kinase Inhibitor in Healthy Chinese...
Liu J, Lv B, Yin H, Zhu X, Wei H, Ding Y
Front Pharmacol . 2021 Feb; 11:604314. PMID: 33536914
Jaktinib is a novel selective janus kinase 1/2 inhibitor. The phase I first-in-human study evaluated the tolerance and pharmacokinetics of jaktinib in healthy Chinese subjects. A randomized, double-blind, placebo-controlled study...